Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis (Q33416223)

26 July 2017

title

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis (English)

1 reference

chronic idiopathic myelofibrosis

26 July 2017

1 reference

1 reference

Chiara Milanesi

15

0 references

Virginia Ferretti

Virginia Ferretti

17

0 references

Lisa Pieri

Lisa Pieri

8

0 references

Daniela Pietra

Daniela Pietra

2

0 references

Vittorio Rosti

Vittorio Rosti

19

0 references

Dolors Colomer

Dolors Colomer

7

0 references

Paola Guglielmelli

Paola Guglielmelli

4

0 references

Monica Corada

0 references

Elena Fugazza

1 reference

ORCID Public Data File 2021

author name string

Elisa Rumi

1

1 reference

26 July 2017

Cristiana Pascutto

3

1 reference

26 July 2017

Alejandra Martínez-Trillos

5

1 reference

26 July 2017

Ilaria Casetti

6

1 reference

26 July 2017

Marta Pratcorona

9

1 reference

26 July 2017

Giada Rotunno

10

1 reference

26 July 2017

Emanuela Sant'Antonio

11

1 reference

26 July 2017

Marta Bellini

12

1 reference

26 July 2017

Chiara Cavalloni

13

1 reference

26 July 2017

Carmela Mannarelli

14

1 reference

26 July 2017

Emanuela Boveri

16

1 reference

26 July 2017

Cesare Astori

18

1 reference

26 July 2017

Francisco Cervantes

20

1 reference

26 July 2017

Giovanni Barosi

21

1 reference

26 July 2017

Alessandro M Vannucchi

22

1 reference

26 July 2017

Mario Cazzola

23

1 reference

26 July 2017

Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators

24

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 July 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

124

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1062-1069

1 reference

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Somatic mutations of calreticulin in myeloproliferative neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

The genetic basis of myelodysplasia and its clinical relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Clinical and biological implications of driver mutations in myelodysplastic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

European consensus on grading bone marrow fibrosis and assessment of cellularity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

The Analysis of Failure Times in the Presence of Competing Risks

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Mutations and prognosis in primary myelofibrosis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Cardiovascular events and intensity of treatment in polycythemia vera

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia

31 October 2018

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

10.1182/BLOOD-2014-05-578435

Identifiers

DOI

1 reference

release_4bs3mc5gmjh2nleutlbwpbmob4

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4bs3mc5gmjh2nleutlbwpbmob4

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4133481

1 reference

26 July 2017

1 reference